1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Fungal Infections - Pipeline Review, H2 2013

Fungal Infections - Pipeline Review, H2 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 131 pages

Fungal Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Fungal Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Fungal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fungal Infections. Fungal Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Fungal Infections.
- A review of the Fungal Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fungal Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Fungal Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fungal Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Fungal Infections - Pipeline Review, H2 2013
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Fungal Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Fungal Infections 9
Fungal Infections Therapeutics under Development by Companies 11
Fungal Infections Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Fungal Infections Therapeutics - Products under Development by Companies 20
Fungal Infections Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Fungal Infections Therapeutics Development 24
AstraZeneca PLC 24
Eli Lilly and Company 25
Vectura Group plc 26
Rib-X Pharmaceuticals, Inc. 27
Samyang Corporation 28
Daewoong Pharmaceutical Co., Ltd. 29
Eisai Co., Ltd. 30
Toyama Chemical Co. Ltd 31
Helix BioMedix, Inc. 32
Immtech Pharmaceuticals, Inc. 33
Lixte Biotechnology Holdings, Inc. 34
MethylGene Inc 35
NovaBay Pharmaceuticals, Inc. 36
Cleveland BioLabs, Inc. 37
Nissui Pharmaceutical Co., Ltd. 38
Choongwae Pharma Corp 39
DONGKOOK Pharmaceutical Co., Ltd. 40
SCYNEXIS, Inc. 41
Palau Pharma S.A 42
F2G Ltd 43
Aegera Therapeutics Inc. 44
Amplyx Pharmaceuticals, Inc. 45
Chimerix, Inc. 46
NovaLead Pharma Pvt. Ltd. 47
Globeimmune, Inc. 48
Aparna Biosciences Corp. 49
Laboratorio Teuto Brasileiro 50
Pacific Beach BioSciences, Inc 51
Fungal Infections - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
HB-1275 - Drug Profile 57
MGCD-290 - Drug Profile 58
DWJ-205 - Drug Profile 60
T-2307 - Drug Profile 61
Anti-Fungal Program - Drug Profile 62
VLF-02 - Drug Profile 63
NVC-612 - Drug Profile 64
NXL-201 - Drug Profile 65
SCY-078 - Drug Profile 66
albaconazole - Drug Profile 67
PB-200a - Drug Profile 69
Spicaterpenoid - Drug Profile 70
SPK-843 - Drug Profile 71
VR-461 - Drug Profile 72
BSG-005 - Drug Profile 73
tolnaftate - Drug Profile 74
E-1210 - Drug Profile 75
SLP-1002 - Drug Profile 76
SLP-0907 - Drug Profile 77
SLP-0901 - Drug Profile 78
LB-201 - Drug Profile 79
GI-9000 - Drug Profile 80
RX-06 - Drug Profile 81
Xenomycin - Drug Profile 83
JWF-1103 - Drug Profile 84
voriconazole - Drug Profile 85
cercosporamide - Drug Profile 86
amphotericin B NanoDisk - Drug Profile 88
Antifungal Program - Drug Profile 89
3-(4-chlorophenyl)-4-Substituted Pyrazole Derivatives - Drug Profile 90
MVX-507 - Drug Profile 91
AfMGB - Drug Profile 92
Drug Targeting HSP90 - Drug Profile 93
Neomaclafungins A-I - Drug Profile 94
12-Aryl-8,9,10,12-Tetrahydrobenzo[a]Xanthene-11-Thiones - Drug Profile 95
F3 Series - Drug Profile 96
SP-3025 - Drug Profile 97
CWF-0711 - Drug Profile 98
Antifungal Drug Program - Drug Profile 99
Antimicrobial Peptides - Drug Profile 100
Anti-Fungal Program - Drug Profile 101
beauvericin - Drug Profile 102
VT-03 - Drug Profile 103
Drug For Fungal Infections - Drug Profile 104
Spongistatin-5 - Drug Profile 105
Spongistatin-7 - Drug Profile 106
Cribrostatin 3 - Drug Profile 107
Cribrostatin 6 - Drug Profile 108
Sodium Resverastatin Phosphate Analogs - Drug Profile 109
Mycobactovir - Drug Profile 110
Mycosis Project - Drug Profile 111
AB-174 - Drug Profile 112
Gamma AApeptides - Drug Profile 113
DKC-210 - Drug Profile 114
Fungal Infections Therapeutics - Drug Profile Updates 115
Fungal Infections Therapeutics - Discontinued Products 118
Fungal Infections Therapeutics - Dormant Products 119
Fungal Infections - Product Development Milestones 120
Featured News and Press Releases 120
Appendix 126
Methodology 126
Coverage 126
Secondary Research 126
Primary Research 126
Expert Panel Validation 126
Contact Us 127
Disclaimer 127

List of Tables

Number of Products Under Development for Fungal Infections, H2 2013 13
Products under Development for Fungal Infections - Comparative Analysis, H2 2013 14
Number of Products under Development by Companies, H2 2013 16
Number of Products under Development by Companies, H2 2013 (Contd..1) 17
Number of Products under Development by Companies, H2 2013 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2013 19
Comparative Analysis by Late Stage Development, H2 2013 20
Comparative Analysis by Mid Clinical Stage Development, H2 2013 21
Comparative Analysis by Early Clinical Stage Development, H2 2013 22
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 23
Products under Development by Companies, H2 2013 24
Products under Development by Companies, H2 2013 (Contd..1) 25
Products under Development by Companies, H2 2013 (Contd..2) 26
Products under Investigation by Universities/Institutes, H2 2013 27
AstraZeneca PLC, H2 2013 28
Eli Lilly and Company, H2 2013 29
Vectura Group plc, H2 2013 30
Rib-X Pharmaceuticals, Inc., H2 2013 31
Samyang Corporation, H2 2013 32
Daewoong Pharmaceutical Co., Ltd., H2 2013 33
Eisai Co., Ltd., H2 2013 34
Toyama Chemical Co. Ltd, H2 2013 35
Helix BioMedix, Inc., H2 2013 36
Immtech Pharmaceuticals, Inc., H2 2013 37
Lixte Biotechnology Holdings, Inc., H2 2013 38
MethylGene Inc, H2 2013 39
NovaBay Pharmaceuticals, Inc., H2 2013 40
Cleveland BioLabs, Inc., H2 2013 41
Nissui Pharmaceutical Co., Ltd., H2 2013 42
Choongwae Pharma Corp, H2 2013 43
DONGKOOK Pharmaceutical Co., Ltd., H2 2013 44
SCYNEXIS, Inc., H2 2013 45
Palau Pharma S.A, H2 2013 46
F2G Ltd, H2 2013 47
Aegera Therapeutics Inc., H2 2013 48
Amplyx Pharmaceuticals, Inc., H2 2013 49
Chimerix, Inc., H2 2013 50
NovaLead Pharma Pvt. Ltd., H2 2013 51
Globeimmune, Inc., H2 2013 52
Aparna Biosciences Corp., H2 2013 53
Laboratorio Teuto Brasileiro, H2 2013 54
Pacific Beach BioSciences, Inc, H2 2013 55
Assessment by Monotherapy Products, H2 2013 56
Assessment by Stage and Route of Administration, H2 2013 58
Assessment by Stage and Molecule Type, H2 2013 60
Fungal Infections Therapeutics - Drug Profile Updates 119
Fungal Infections Therapeutics - Discontinued Products 122
Fungal Infections Therapeutics - Dormant Products 123

List of Figures

Number of Products under Development for Fungal Infections, H2 2013 13
Products under Development for Fungal Infections - Comparative Analysis, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 19
Late Stage Products, H2 2013 20
Mid Clinical Stage Products, H2 2013 21
Early Clinical Stage Products, H2 2013 22
Discovery and Pre-Clinical Stage Products, H2 2013 23
Assessment by Monotherapy Products, H2 2013 56
Assessment by Route of Administration, H2 2013 57
Assessment by Stage and Route of Administration, H2 2013 58
Assessment by Molecule Type, H2 2013 59
Assessment by Stage and Molecule Type, H2 2013 60

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Nectar Lifesciences Ltd. (India)

Nectar Lifesciences Ltd. (India)

  • $ 3500
  • Company report
  • March 2016
  • by Global Industry Analysts

This report presents quick facts about Nectar Lifesciences Ltd., which is principally involved in Pharmaceuticals Business. Illustrated with 85 tables, the report showcases the company's sales performance, ...

Dermatomycoses Global Clinical Trials Review, H1, 2016

Dermatomycoses Global Clinical Trials Review, H1, 2016

  • $ 2500
  • Company report
  • February 2016
  • by Global Data

Dermatomycoses Global Clinical Trials Review, H1, 2016 Summary GlobalData's clinical trial report, “Dermatomycoses Global Clinical Trials Review, H1, 2016" provides an overview of Dermatomycoses clinical ...

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016’, ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.